Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

Q3 2024 Earnings Call Transcript October 30, 2024 LivaNova PLC misses on earnings expectations. Reported EPS is $0.604 EPS, ...

1 of 1' marketing platform, and our commitment to our... LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized ...

LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using ...

For OSPREY which is about sleep apnoea, they will get more critical data next year, but things are apparently looking good in terms of initial predictive outcomes and the program is getting ...

Welcome to LivaNova's conference call for the third ... In OSA, we are encouraged by the early stoppage in enrollment of the OSPREY study in March, which was based on a determination that there ...

FILE - U.S. MV-22 Osprey transport aircraft are parked at the U.S. Marine Corps Air Station Futenma in Ginowan, south of Okinawa, southern Japan, Sept. 6, 2023. (AP Photo/Hiro Komae, File ...

WASHINGTON (AP) — Japan has grounded its fleet of V-22 Osprey aircraft again after an incident last Sunday where one of the hybrid helicopter-aircraft tilted unexpectedly and hit the ground ...